Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 2;7(12):e2449182.
doi: 10.1001/jamanetworkopen.2024.49182.

Pertussis Immunity 5 Years After Booster Vaccination With Recombinant Pertussis Vaccines

Punnee Pitisuttithum  1 , Chukiat Sirivichayakul  1 , Jittima Dhitavat  1 , Arom Pitisuthitham  1 , Souad Mansouri  2 , Hong Thai Pham  2
Affiliations

Pertussis Immunity 5 Years After Booster Vaccination With Recombinant Pertussis Vaccines

Punnee Pitisuttithum et al. JAMA Netw Open. .
No abstract available

Plain language summary

This cohort study compares levels of immunity 5 years after vaccination among adolescents given genetically detoxified pertussis boosters with those given chemically inactivated pertussis boosters.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Prof Pitisuttithum reported receiving grants from Mahidol University during the conduct of the study. Dr Sirivichayakul reported receiving grants from Bionet-Asia during the conduct of the study. Drs Mansouri and Pham reported being employed by BioNet-Asia during the conduct of the study. No other disclosures were reported.

Figures

Figure.
Figure.. Persistence of Pertussis Neutralizing Antibodies 1, 2, 3, and 5 Years After Booster Vaccination With Recombinant or Chemically Detoxified Pertussis Vaccine
The graph shows geometric mean titer (GMT) ratios and 95% CIs of pertussis toxin neutralizing antibodies in the years following vaccination with 1 dose of the genetically detoxified pertussis vaccine (aPgen; 21 participants); combined tetanus-diphtheria-pertussis formulation (TdaPgen; 15 participants); or chemically inactivated tetanus-diphtheria-pertussis vaccine (Tdapchem; 19 participants) vs baseline (prevaccination). The dotted line represents a GMT ratio of 1, in which postvaccination and prevaccination levels are equal. Differences between groups were compared using the Bonferroni post hoc test on pairwise comparisons. aP < .001.
See this image and copyright information in PMC

References

    1. Klein NP, Bartlett J, Fireman B, Baxter R. Waning Tdap effectiveness in adolescents. Pediatrics. 2016;137(3):e20153326. doi:10.1542/peds.2015-3326 - DOI - PubMed
    1. Eberhardt CS, Siegrist CA. What Is wrong with pertussis vaccine immunity? inducing and recalling vaccine-specific immunity. Cold Spring Harb Perspect Biol. 2017;9(12):a029629. doi:10.1101/cshperspect.a029629 - DOI - PMC - PubMed
    1. Esposito S, Stefanelli P, Fry NK, et al. ; World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG) . Pertussis prevention: reasons for resurgence, and differences in the current acellular pertussis vaccines. Front Immunol. 2019;10:1344. doi:10.3389/fimmu.2019.01344 - DOI - PMC - PubMed
    1. Sricharoenchai S, Sirivichayakul C, Chokephaibulkit K, et al. . A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial. Lancet Infect Dis. 2018;18(1):58-67. doi:10.1016/S1473-3099(17)30612-6 - DOI - PubMed
    1. Pitisuttithum P, Dhitavat J, Sirivichayakul C, et al. . Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines. EClinicalMedicine. 2021;37:100976. doi:10.1016/j.eclinm.2021.100976 - DOI - PMC - PubMed